resources

Aurobindo Pharma Ltd.

NSE: AUROPHARMA

BSE: 524804

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

1,675.40+12.5 (+0.75%)

15 Oct, 12:29 PM

Overview Analysis Statements Technicals Forecast Peers Resources

News

Annual Reports and Financial Documents

Aurobindo Pharma Ltd. annual reports, quarterly results, earnings call transcripts and investor presentations. All official filings in one place.

	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
Annual Reports	FY 2013	FY 2014	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Quarterly Results	—	—	—	—	—	Dec	Mar Jun Sept Dec	Mar Jun Sept Dec	Mar Jun Sept Dec	Mar Sept Dec	Mar Jun Sept Dec	Mar Jun Sept Dec	Dec	Mar
Conference Calls	—	—	—	—	—	—	—	—	25Feb 11Jun 25Aug 19Nov	17Feb 6Jun 19Aug 18Nov	17Feb 1Jun 18Aug 15Nov	16Feb 31May 16Aug 18Nov	13Feb 2Jun 8Aug 11Nov	16Feb 27May 13Aug
Presentations	—	—	—	—	—	—	—	—	10Feb 31May 12Aug 8Nov	9Feb 30May 11Aug 7Sept 12Nov	9Feb 27May 12Aug 9Nov	10Feb 13Mar 25May 10Aug 9Nov	6Feb 26May 4Aug 5Nov	9Feb 10Feb 21May 5Aug

Corporate Announcements and Regulatory Filings

Aurobindo Pharma Ltd. BSE/NSE disclosures, board meeting outcomes, insider trading notifications, acquisitions and other regulatory filings.

Newspaper Publication9 Oct 2026
Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of Notice published in newspapers.
Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 20185 Oct 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Submission of certificate in terms of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Press Release / Media Release3 Oct 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Submission of Press Release that is being issued by the Company in connection with receipt of USFDA final approval for Perampanel Tablets 2 mg, 4 mg, 6 mg, 8 mg 10 mg and 12 mg.
General2 Oct 2026
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
Intimation of completion of acquisition.
Acquisition2 Oct 2026
Announcement under Regulation 30 (LODR)-Acquisition
Intimation of acquisition of a step down subsidiary in USA.
Acquisition1 Oct 2026
Announcement under Regulation 30 (LODR)-Acquisition
Intimation of allotment of shares by A1 Biochem Labs (India) Private Limted, a step down subsidiary of the Company.
Press Release / Media Release30 Sept 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Submission of press release that is being issued by the Company in connection with launching of ADQUEY in the U.S and Establishes Dedicated Dermatology Business.
General29 Sept 2026
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation of order passed by Appellate Joint Commissioner (ST), Malkajgiri Division, Hyderabad, Telangana.
Closure of Trading Window24 Sept 2026
Closure of Trading Window
Intimation of closure of trading window.
Analyst / Investor Meet21 Sept 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of investor Analyst meet scheduled on 24.09.2026.
General15 Sept 2026
Completion Of US FDA Inspection At Unit-II Of Apitoria Pharma Private Limited, A Wholly Owned Subsidiary Of The Company
Submission of completion of US FDA inspection of Unit-II of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.
Press Release / Media Release15 Sept 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Submission of Press Release that is being issued in connection with receipt of US FDA final approval for Beclomethasone Dipropionate HFA Inhalation Aerosol , 40 mcg and 80 mcg.
Acquisition12 Sept 2026
Announcement under Regulation 30 (LODR)-Acquisition
Intimation of subscription of 10,000 shares of USD 100 each of A1 Biochem USA Inc by A1 Biochem Labs (India) Private Limited, a step down subsidiary of the Company.
General11 Sept 2026
Completion Of US FDA Inspection At Unit-IV Of Apitoria Pharma Private Limited, A Wholly Owned Subsidiary Of The Company
Intimation of completion of US FDA inspection of Unit-IV of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.
Analyst / Investor Meet11 Sept 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of investor / analyst meet scheduled on 22.09.2026.
Analyst / Investor Meet11 Sept 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of investor / analyst meet scheduled on 21.09.2026.
Analyst / Investor Meet11 Sept 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of investor / analyst meet scheduled on 17.09.2026.
Analyst / Investor Meet11 Sept 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of investor / analyst meet scheduled on 18.09.2026.
Analyst / Investor Meet11 Sept 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Investor / analyst meet scheduled on 17.09.2026.
Newspaper Publication3 Sept 2026
Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of notice published in newspapers.

Frequently Asked Questions

Where can I download the annual report of Aurobindo Pharma Ltd.?

Annual reports of Aurobindo Pharma Ltd. are available for download in the Annual Reports and Financial Documents section of the Resources tab, organised by financial year.

Where can I find the quarterly results of Aurobindo Pharma Ltd.?

Quarterly earnings results and presentations of Aurobindo Pharma Ltd. are available in the Annual Reports and Financial Documents section of the Resources tab. Detailed financials are also in the Statements tab.

Does Aurobindo Pharma Ltd. publish earnings call transcripts?

Earnings call transcripts of Aurobindo Pharma Ltd., where available, are listed in the Annual Reports and Financial Documents section of the Resources tab.

Where can I find investor presentations of Aurobindo Pharma Ltd.?

Investor presentations and annual day presentations of Aurobindo Pharma Ltd. are listed in the Resources tab under Annual Reports and Financial Documents.

What are the recent corporate announcements of Aurobindo Pharma Ltd.?

Corporate announcements and regulatory filings of Aurobindo Pharma Ltd. as submitted to BSE and NSE are available in the Corporate Announcements and Regulatory Filings section of the Resources tab.

How do I access the regulatory filings of Aurobindo Pharma Ltd.?

Regulatory filings including board meeting outcomes, insider trading disclosures and other exchange notifications of Aurobindo Pharma Ltd. are in the Corporate Announcements and Regulatory Filings section of the Resources tab.

What is the ISIN of Aurobindo Pharma Ltd.?

The ISIN (International Securities Identification Number) of Aurobindo Pharma Ltd. is INE406A01037. This is the unique identifier used across exchanges and depositories.

On which stock exchange is Aurobindo Pharma Ltd. listed?

Aurobindo Pharma Ltd. is listed on NSE and BSE. The NSE symbol is AUROPHARMA and the BSE code is -.

Where can I find the shareholding pattern of Aurobindo Pharma Ltd.?

The quarterly shareholding pattern of Aurobindo Pharma Ltd. showing promoter, FII, DII, mutual fund and public holdings is available in the Shareholding Pattern section on the Overview tab.

How current is the data for Aurobindo Pharma Ltd. on Sharpely?

Share price data for Aurobindo Pharma Ltd. is updated as of 15 Oct 2026. Financial statements, shareholding and other fundamental data are updated after each quarterly disclosure.